Asset Details
Do you wish to reserve the book?
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
Do you wish to request the book?
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
2016
Overview
Several clinical trials have demonstrated that some patients with chronic myeloid leukemia in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend therapy and attempt treatment‐free remission (TFR). Many TFR studies to date have enrolled imatinib‐treated patients; however, the feasibility of TFR following nilotinib or dasatinib has also been demonstrated. In this review, we discuss available data from TFR trials and what these data reveal about the molecular biology of TFR. With an increasing number of ongoing TFR clinical trials, TFR may become an achievable goal for patients with CML‐CP. Treatment‐free remission (TFR) is an emerging treatment goal for patients with chronic myeloid leukemia in chronic phase (CML‐CP). Numerous TFR clinical trials have demonstrated that some patients with CML‐CP with sustained deep molecular responses on tyrosine kinase inhibitor (TKI) therapy can safely suspend TKI therapy without a loss of response. In this review, we discuss available data from TFR trials in patients with deep molecular responses to TKI therapies, including imatinib, dasatinib, and nilotinib.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
Antineoplastic Agents - therapeutic use
/ Disease
/ Fusion Proteins, bcr-abl - genetics
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Imatinib
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
/ Leukemia, Myeloid, Chronic-Phase - diagnosis
/ Leukemia, Myeloid, Chronic-Phase - drug therapy
/ Leukemia, Myeloid, Chronic-Phase - genetics
/ Patients
/ Protein Kinase Inhibitors - therapeutic use
/ Review
